Sio Gene Therapies Inc. (NASDAQ:SIOX Get Rating) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 239,800 shares, an increase of 33.4% from the May 31st total of 179,800 shares. Approximately 0.5% of the companys shares are short sold. Based on an average daily volume of 825,400 shares, the days-to-cover ratio is currently 0.3 days. <\/p>\n
A number of large investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC increased its position in Sio Gene Therapies by 7.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,914,000 shares of the companys stock worth $7,629,000 after acquiring an additional 425,000 shares during the period. Privium Fund Management UK Ltd acquired a new stake in Sio Gene Therapies during the fourth quarter worth about $2,367,000. Clearline Capital LP grew its stake in Sio Gene Therapies by 79.7% during the first quarter. Clearline Capital LP now owns 392,691 shares of the companys stock worth $263,000 after buying an additional 174,185 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Sio Gene Therapies during the third quarter worth about $103,000. <\/p>\n
NASDAQ SIOX opened at $0.37 on Friday. The firm has a market capitalization of $26.92 million and a P\/E ratio of -0.43. The firms fifty day moving average price is $0.34 and its two-hundred day moving average price is $0.69. Sio Gene Therapies has a 1 year low of $0.23 and a 1 year high of $2.74. <\/p>\n
Sio Gene Therapies Company Profile (Get Rating)<\/p>\n
Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I\/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I\/II clinical trials for the treatment of GM2 gangliosidosis.<\/p>\n
See Also<\/p>\n
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.<\/p>\n
<\/p>\n
See the original post:<\/p>\n
Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Sio Gene Therapies Inc. (NASDAQ:SIOX Get Rating) was the recipient of a significant increase in short interest in the month of June Continue reading